LXRX LEXICON PHARMACEUTICALS, INC. Insider Trading

Director Debbane buys 2,000 shares of LXRX at $1.49; stock down 16.5% from 52-week high amid unprofitable operations.

DEBBANE RAYMOND acquired 2,000 shares at $1.49 on 2026-02-25, bringing his holdings to 1,906,186 shares. This represents a modest addition (+0.1% vs pre-transaction holdings) at a price 16.5% below the 52-week high. Notably, this buy is the fifth consecutive LXRX purchase in four days (2026-02-17 through 2026-02-25), suggesting sustained accumulation during a period of weakness. The company remains unprofitable, with a net income of $-12,769,000.00 in the latest quarter against revenue of $14,182,000.00, though annual revenue growth was exceptional at +2481.5%. Across his broader portfolio, Debbane has posted a 100.00% 90-day win rate on 9 prior buys (avg 90d return +37.1%), but those outcomes at other tickers do not yet provide validation at LXRX, where all five recent trades have insufficient time for measurable returns. The rapid-fire sequence of small purchases at declining prices warrants observation of whether this pattern represents genuine confidence or tactical accumulation into depressed valuations.

Director Raymond Debbane buys 100,000 shares of LXRX at $1.47; stock -14.8% from high, company unprofitable

Director Raymond Debbane purchased 100,000 shares at $1.47 on 2026-02-23, increasing his holdings by 5.5% to 1,904,186 shares. The transaction occurs as LXRX trades 14.8% below its 52-week high of $1.76, despite the company's recent spike in annual revenue growth of +2481.5%, which masks persistent unprofitability: the latest quarter posted net income of $-12,769,000.00 against revenue of $14,182,000.00, and the company was unprofitable over its most recent full fiscal year. This purchase follows four other insider buys at LXRX within 6 days (2026-02-17 through 2026-02-20), but outcomes on those trades are not yet measurable. Debbane's cross-ticker track record shows a 100.00% 90-day win rate across 9 prior buys, though those occurred at different companies, providing limited direct inference for LXRX performance.

Director Raymond Debbane bought 150,000 shares (150.0K) of LXRX across 2 transactions at blended avg $1.47; now holds 1,804,186 shares.

Director Debbane executed 2 separate purchases totaling 150,000 shares for $219,755.00 on consecutive trading days (Feb 19–20, 2026) at an average price of $1.47, raising his stake by 9.1% to 1.80M shares. The stock currently trades at $1.51, modestly above his blended purchase price, though it has declined 11.2% over 30 days and sits 14.2% below its 52-week high of $1.76. Across his broader open-market history spanning multiple tickers, Debbane has executed 7 prior buys with a 100% 90-day win rate and average 90-day return of +37.1%, though his most recent same-ticker purchase at LXRX (2023-10-12) showed a 90-day return of +40.3%—his only measurable outcome at this company. The company remains unprofitable (net income of $-12.8M in its latest full year) despite revenue growth of +2481.5% year-over-year, and current quarterly revenue stands at $14.2M against a market cap of $548.7M. This represents continued accumulation by a director during a period of recent price weakness in an early-stage, loss-making company.

Director DEBBANE RAYMOND bought 268,497 shares at $1.31 avg (3 purchases, $352.9K)

Director Raymond executed 3 separate open-market purchases totaling 268,497 shares for $352,889.04 within a five-day window (Feb 13–18), increasing his holdings by 19.4% from 1,385,689 to 1,654,186 shares at a blended average price of $1.31. His prior trades at LXRX show a strong pattern: all 3 prior buys—executed in October 2023—were well-timed at the 90-day mark, with 90-day returns of +40.3%, +36.9%, and +34.2% respectively, and a 100% win rate across his cross-ticker track record (avg 90d return +37.1%). The current price of $1.32 is down 25.0% from the 52-week high of $1.76, positioning this accumulation near depressed levels. However, LXRX remains unprofitable (net income $-12.8M on revenue of $14.2M last quarter), though annual revenue growth stands at +2481.5% year-over-year, suggesting significant operational momentum despite current losses.

Director Invus Global bought 1,538,462 shares (1.54M) of LXRX at $1.30 for $2,000,000.60 on 2026-02-02

Invus Global Management, LLC purchased 1,538,462 shares for $2,000,000.60 at $1.30 per share, a substantial discretionary acquisition by a director of Lexicon Pharmaceuticals. The transaction is notable given the company's operating profile: Lexicon generated $14,182,000.00 in latest quarterly revenue but reported a net loss of $-12,769,000.00 in the same period, and was unprofitable over its most recent full fiscal year. The stock currently trades at $1.27, slightly below the $1.30 purchase price. The 52-week range of $0.29–$1.76 places the transaction near the upper portion of recent historical trading, though the stock is -27.8% from its 52-week high. Investors should evaluate whether this director-level commitment reflects confidence in Lexicon's strategic direction or product pipeline, balanced against the sustained operating losses and modest revenue base.